Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127848661 | 12784866 | 1 | I | 201405 | 20160920 | 20160927 | 20160927 | EXP | PHHY2016HK131701 | NOVARTIS | 55.00 | YR | F | Y | 0.00000 | 20160927 | MD | HK | HK |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127848661 | 12784866 | 1 | PS | AFINITOR | EVEROLIMUS | 1 | Unknown | UNK | D | 22334 | |||||||||
| 127848661 | 12784866 | 2 | SS | AFINITOR | EVEROLIMUS | 1 | Unknown | 5 MG, QD | D | 22334 | 5 | MG | QD | ||||||
| 127848661 | 12784866 | 3 | SS | AFINITOR | EVEROLIMUS | 1 | Unknown | 5 MG, QOD | D | 22334 | 5 | MG | |||||||
| 127848661 | 12784866 | 4 | SS | AROMASIN | EXEMESTANE | 1 | Unknown | UNK | D | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127848661 | 12784866 | 1 | Breast cancer |
| 127848661 | 12784866 | 4 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127848661 | 12784866 | DE |
| 127848661 | 12784866 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127848661 | 12784866 | Blood bilirubin increased | |
| 127848661 | 12784866 | Blood cholesterol increased | |
| 127848661 | 12784866 | Blood triglycerides increased | |
| 127848661 | 12784866 | Cough | |
| 127848661 | 12784866 | Death | |
| 127848661 | 12784866 | Dyspnoea | |
| 127848661 | 12784866 | General physical health deterioration | |
| 127848661 | 12784866 | Hepatic failure | |
| 127848661 | 12784866 | Hepatomegaly | |
| 127848661 | 12784866 | Hypercalcaemia | |
| 127848661 | 12784866 | Lung infiltration | |
| 127848661 | 12784866 | Lymphadenopathy | |
| 127848661 | 12784866 | Malignant neoplasm progression | |
| 127848661 | 12784866 | Metastases to liver | |
| 127848661 | 12784866 | Metastases to lymph nodes | |
| 127848661 | 12784866 | Metastases to skin | |
| 127848661 | 12784866 | Pneumonitis | |
| 127848661 | 12784866 | Skin mass | |
| 127848661 | 12784866 | Stomatitis | |
| 127848661 | 12784866 | Tachypnoea |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127848661 | 12784866 | 4 | 201309 | 0 |